2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Profiling, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, AML, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

6057 Chimeric antigen receptor T-cell therapy versus allogeneic stem cell transplant in patients with Richter transformation in complete or partial remission: A matched adjusted comparison

Robert S. Rosen, MD, PhD, Graham Wehmeyer, MD2, Dimitrios Papaioannou, MD3, Marc Schwartz, MD4, Nora Chokr, MD5, Jingmei Hsu, MD6, Maher Abdul-Hay, MD7, Peter Martin, FRCPC, MD, MS8, John Leonard, MD9, Adam Kittai, MD10, Samuel Yamshon, MD11
1 NYU Langone Health, New York, New York, United States
2 Mount Sinai Hospital, New York, New York, United States
3 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
4 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
5 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
6 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
7 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
8 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
9 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
10 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
11 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States

Introduction:

Despite advances in the treatment of chronic lymphocytic leukemia, Richter Transformation (RT) remains associated with poor outcomes. Consolidation strategies in RT include allogeneic stem cell transplant (alloHCT) for eligible patients or chimeric antigen receptor T-cell therapy (CART). While both treatments can be offered to patients who achieve complete or partial remission (CR/PR), no comparison of outcomes between these modalities has been conducted, limiting guidance for clinical practice. We investigated the outcomes of CART and alloHCT for patients with CR/PR in RT using de-identified patient data from the Center for International Blood and Marrow Transplant Research (CIBMTR) made publicly available for secondary analysis.

Methods:

Publicly available patient level data from the CIBMTR registry was obtained for the studies LY22-02d (CART dataset) and LY18-03 (alloHCT dataset) for patients who received alloHCT or CART for RT while in CR/PR. Patients who received alloHCT prior to CART and patients who received autologous stem cell transplant prior to CART or alloHCT were excluded. Inverse probability of treatment weighting (IPTW) was used to account for anticipated baseline differences in treatment selection between cohorts. Key risk factors were selected using the ERIC guidelines, including age, disease status at time of treatment, Karnofsky Score >90% and the presence of del17p. Propensity scores were estimated by logistic regression for receiving CART. Stabilized inverse probability weights were calculated, and covariate stabilization was assessed by absolute standardized mean differences. The primary outcomes were progression free survival (PFS) and overall survival (OS), and secondary outcomes included treatment-related mortality and relapse. IPTW-survival curves and IPTW-Cox proportional hazard ratios with a time-to-event analysis were used to estimate adjusted outcomes.

Results:

122 patients with RT in CR/PR were included, 84 patients received alloHCT from 2007-2017 and 38 patients received CART from 2018-2023. Patients treated with alloHCT were younger (median 60 vs. 66 for CART (p<0.01)) and received fewer prior lines of treatment compared to those treated with CART (median 1.0 vs. 3.0, p<0.01). There was no significant difference in Karnofsky Score, del17p, sex, time from transformation to treatment, or BTK inhibitor exposure. In the alloHCT group, 21% received myeloablative conditioning and 79% received nonmyeloablative conditioning regimens.

Patients were matched with IPTW to absolute mean difference <0.1 indicating good balance of covariates. After matching, median OS was 60.7 months (95% CI 25.0–not estimable (NE)) for alloHCT and 38.4 months (95% CI 20.8–NE) for CART (p= 0.9), with 1-year OS of 69.4% (95% CI 59.7–80.7) for alloHCT and 76.3% for CART (95% CI 61.3–94.9) (p=0.49). Median PFS was 24.8 months (95% CI 8.5–NE) in alloHCT and 26.2 months in CART (95% CI 12.5–NE), with 1-year PFS of 55.3% (95% CI 45.2–67.6) in alloHCT and 65.8% in CART (95% CI 50.3–86.1) (p=0.32). There was no significant difference in OS between alloHCT and CART (hazard ratio (HR) 1.09, 95% CI 0.50-2.34 p=0.83) and no difference in rate of relapse (HR 1.80 95% CI 0.83-3.93 p=0.14). Treatment-related mortality (TRM) was lower with CART, with 1-year cumulative incidence of TRM in alloHCT of 22.4% (95% CI 14.6–34.5) compared to 1.2% (95% CI 0.2–8.4) for CART. In the alloHCT patients there was no difference in TRM between myeloablative and non-myeloablative conditioning (p = 0.54). Rates of TRM favored CART, with HR 0.14 (95% CI 0.03-0.67 p=0.01).

Discussion:

Outcomes of alloHCT and CART consolidation for patients with RT in CR/PR were compared using the CIBMTR database after achieving balance of co-variates via IPTW. There was no significant difference in median or 1-year PFS or OS between alloHCT and CART, but there was a significantly lower rate of TRM in CART recipients. Despite treatments administered in different eras, the same proportion of patients received BTK inhibitors. These data suggest for patients in CR/PR, a personalized and patient-specific approach driven by individual preferences, clinical characteristics, and comorbidities should be conducted as both CART and alloHCT offer opportunities for durable remission. Further evaluation with a synchronous, matched cohort is needed to help clarify optimal patient care.

Robert S. Rosen, MD, PhD: No relevant conflicts of interest to declare.